Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
TOPOTECAN HYDROCHLORIDE (UNII: 956S425ZCY) (TOPOTECAN - UNII:7M7YKX2N15)
Hospira, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. Topotecan Injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. Reactions have included anaphylactoid reactions [see Adverse Reactions (6.2)] . Risk Summary Based on animal data and its mechanism of action, Topotecan Injection can cause fetal harm when administered to a pregnant woman. There are no available clinical data on the use of topotecan in pregnancy. Topotecan caused embryolethality, fetotoxicity, and teratogenicity in rats and rabbits when administered during organogenesis at doses similar to the clinical dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data An
Topotecan Injection is supplied in 4 mg/4 mL (1 mg/mL topotecan free base) single-dose vials. Each vial contains 4 mL of the sterile, clear, yellow to yellow-green solution. NDC 0409-0302-01 (Package of 1 single-dose vial) Store refrigerated between 2°C and 8°C (36°F and 46°F) in the original carton to protect from light. Discard unused portion. Topotecan Injection is a cytotoxic drug. Follow applicable handling and disposal procedures.1
New Drug Application
TOPOTECAN- TOPOTECAN INJECTION, SOLUTION, CONCENTRATE HOSPIRA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TOPOTECAN INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TOPOTECAN INJECTION. TOPOTECAN INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING: MYELOSUPPRESSION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ TOPOTECAN CAN CAUSE SEVERE MYELOSUPPRESSION. ADMINISTER FIRST CYCLE ONLY TO PATIENTS WITH BASELINE NEUTROPHIL COUNTS GREATER THAN OR EQUAL TO 1,500/MM AND PLATELET COUNT GREATER THAN OR EQUAL TO 100,000/MM . MONITOR BLOOD CELL COUNTS. (2.2, 5.1) INDICATIONS AND USAGE Topotecan Injection is a topoisomerase inhibitor indicated for treatment of small cell lung cancer (SCLC) platinum- sensitive disease in patients who progressed at least 60 days after initiation of first-line chemotherapy. (1) DOSAGE AND ADMINISTRATION Recommended dosage: 1.5 mg/m by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle. (2.2) Renal impairment: Reduce dose for creatinine clearance (CLcr) of 20 to 39 mL/min. (2.4) DOSAGE FORMS AND STRENGTHS Injection: 4 mg/4 mL (1 mg/mL topotecan free base) solution in single-dose vial. (3) CONTRAINDICATIONS History of severe hypersensitivity reactions to topotecan. (4) WARNINGS AND PRECAUTIONS Interstitial lung disease (ILD): Fatal cases have occurred. Permanently discontinue if ILD confirmed. (5.2) Extravasation and tissue injury: Severe cases have occurred. If extravasation occurs, immediately stop administration and institute recommended management procedures. (5.3) Embryo-fetal toxicity: Can cause fetal harm. Advise women of potential risk to the fetus. (5.4, 8.1, 8.3) ADVERSE REACTIONS The most common Grade 3 or 4 hematologic adverse reactions (incidence >5%) were: neutropenia , anemia , thrombocytopenia, and febrile neutropenia. (6.1) The most common non-hematologic adverse reactions (incidence >5%) (all grades) Citiți documentul complet